Tarsons swings to ₹1.4 Cr consolidated loss in Q1 FY27 despite 20.7% YoY revenue growth
Tarsons Products' consolidated result for the quarter ended June 30, 2026 shows revenue of ₹110.24 Cr, up 20.7% YoY from ₹91.36 Cr but down 8.8% QoQ from a seasonally stronger ₹120.93 Cr in Q4 FY26. Despite the topline growth, the group swung to a net loss of ₹1.44 Cr (EPS ₹(0.27)) against a profit of ₹1.78 Cr a year ago and ₹4.18 Cr last quarter. Neither the current nor year-ago quarter carried exceptional items, and last quarter's ₹0.22 Cr labour-code exceptional cost is also absent here, so this is a purely operational swing, not a one-off.
Cost of materials, traded goods and inventory movements rose to 35.1% of revenue from 32.1% a year ago, consistent with management's Q4 FY26 concall warning that raw-material price increases would pressure Q1 FY27 margins toward Q4 FY26 levels. Operating margin came in around 23.6%, however — below both the year-ago 27.0% and the ~28.5% level management pointed to, a miss against its own framing. The bigger drag sat below the operating line: depreciation jumped 42% YoY to ₹27.02 Cr (24.5% of revenue vs 20.8% a year ago) as capex commissioning proceeds, and finance costs rose 23.5% YoY to ₹6.27 Cr. Together, D&A and finance costs absorbed the operating profit and pushed the group to a ₹1.32 Cr pre-tax loss and, after a ₹0.12 Cr tax charge, a ₹1.44 Cr net loss.
Standalone (India-only) results diverge sharply: standalone PAT was a profit of ₹0.68 Cr (EPS ₹0.13) on revenue of ₹86.15 Cr, indicating the consolidated loss originates from the overseas subsidiaries (Tarsons Life Science Pte Ltd, Singapore, and its German units) and consolidated-level D&A/finance allocations rather than the core India business. The auditor's review report notes two smaller step-down subsidiaries, not yet reviewed by their own auditors, posted a combined net loss of roughly ₹0.18 Cr this quarter, which management calls immaterial to the Group. No press release or MD&A accompanied the filing beyond the SEBI outcome letter and financial statements. A web search found no quarter-specific street estimate for Q1 FY27 revenue or PAT; general analyst commentary (citing JM Financial and Kotak Securities targets) points to a full-year FY27 PAT growth expectation of 15-20%, a bar this quarter's swing to a consolidated loss does not support on its own, though one quarter does not decide the year. The quarter also saw an HR head resignation, unrelated to the financial print.
Management's guidance flagged Q1 FY27 margin pressure converging toward Q4 FY26 levels and full capex commissioning in H1 FY27 to eventually drive operating leverage; this quarter confirms the margin pressure but shows the depreciation and finance-cost step-up landing before any offsetting leverage shows up. Watch points into Q2 FY27: whether OPM recovers toward the >65% gross-margin floor management still expects from gradual price hikes, whether the overseas subsidiary losses narrow, and whether FY27 standalone depreciation (₹24.56 Cr this quarter, ~₹98 Cr annualized) lands within the guided ₹105-110 Cr band.
